Idiopathic Pulmonary Fibrosis Epidemiology Forecast

DelveInsight’s ‘Idiopathic Pulmonary Fibrosis - Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Idiopathic Pulmonary Fibrosis Understanding

Idiopathic Pulmonary Fibrosis Overview

Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people in later stage of their life. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.

 

The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough

 

Idiopathic Pulmonary Fibrosis Diagnosis

Careful evaluation of clinical, laboratory, x-ray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathologic data.

 

There are several diagnostic tools available and the consensus guidelines have been well defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity. When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like x-rays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.

Idiopathic Pulmonary Fibrosis Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis, and severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis scenario of Idiopathic Pulmonary Fibrosis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Idiopathic Pulmonary Fibrosis Detailed Epidemiology Segmentation

  • The total diagnosed prevalent cases of IPF in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019–2032).
  • The highest diagnosed prevalent cases of IPF was accounted by the US in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.
  • Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In the epidemiology model of DelveInsight, we have considered four age groups for the categorization of IPF i.e. 18–39 years, 40–59 years, 60–79 years, and >80 years. As per our analysis, a highest percentage of diagnosed prevalent cases was observed in age group 60–79, in all the 7MM countries.
  • As per DelveInsight’s analysis the males are predominantly affected highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.
  • Japan accounted for 21,246 cases of total diagnosed prevalent cases of IPF in 2021 which are anticipated to rise by the end of 2032.

Scope of the Report

  • The report covers the descriptive overview of Idiopathic Pulmonary Fibrosis, explaining its causes, signs, and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by segmented by diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF), age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis, and severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.

Report Highlights

  • 11-Year Forecast of Idiopathic Pulmonary Fibrosis.
  • The 7MM Coverage.
  • Diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
  • Gender-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
  • Age-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.
  • Severity-specific diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis.

Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of Idiopathic Pulmonary Fibrosis?
  • What is the historical Idiopathic Pulmonary Fibrosis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Idiopathic Pulmonary Fibrosis at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Idiopathic Pulmonary Fibrosis?
  • Out of the countries mentioned above, which country would have the highest patient population of Idiopathic Pulmonary Fibrosis during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy

The Idiopathic Pulmonary Fibrosis report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MMIdiopathic Pulmonary Fibrosis epidemiology.
  • The Idiopathic Pulmonary Fibrosis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Idiopathic Pulmonary Fibrosis epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Idiopathic Pulmonary Fibrosis Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2019

3.2. Patient Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2032

4. Executive Summary of Idiopathic Pulmonary Fibrosis

5. Key Events

6. Disease Background and Overview of Idiopathic Pulmonary Fibrosis

6.1. Introduction of Idiopathic Pulmonary Fibrosis

6.2. Staging of Idiopathic Pulmonary Fibrosis

6.3. Causes and Risk Factors of Idiopathic Pulmonary Fibrosis

6.4. Symptoms of Idiopathic Pulmonary Fibrosis

6.5. Pathogenesis of Idiopathic Pulmonary Fibrosis

6.6. Diagnosis of Idiopathic Pulmonary Fibrosis

6.6.1. Diagnostic Algorithm

6.6.2. Diagnostic Guidelines

6.6.2.1. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association, 2018

6.6.2.2. French practical guidelines for the diagnosis of idiopathic pulmonary fibrosis, 2017

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Assumptions and Rationale: 7MM

7.3.1. The United States

7.3.2. Five major European countries

7.3.3. Japan

7.4. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the 7MM

7.5. The United States

7.5.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United States

7.5.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United States

7.5.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United States

7.5.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United States

7.6. Major Five European Countries

7.6.1. Germany

7.6.1.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.1.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.1.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.1.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.2. France

7.6.2.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.2.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.2.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.2.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.3. Italy

7.6.3.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.3.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.3.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.3.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.4. Spain

7.6.4.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.4.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.4.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.4.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.5. The United Kingdom

7.6.5.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.5.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.5.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.6.5.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis

7.7. Japan

7.7.1. Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan

7.7.2. Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan

7.7.3. Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan

7.7.4. Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan

8. Patient Journey

9. KOL Views

10. Appendix

10.1. Bibliography

10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

Table 1: Summary of Idiopathic Pulmonary Fibrosis (IPF) Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Classification of Idiopathic Pulmonary Fibrosis based on FVC Score

Table 4: The GAP (Gender, Age, and Physiology) score

Table 5: The GAP index and staging system

Table 6: Mortality risk scoring system for patients with idiopathic pulmonary fibrosis

Table 7: Idiopathic pulmonary fibrosis diagnosis based upon HRCT and biopsy patterns.

Table 8: Interpretation of Strong and Conditional Recommendations for Stakeholders (Patients, Clinicians, and Health Care Policymakers)

Table 9: Comparison of Recommendations in 2015 and 2011 IPF Guidelines

Table 10: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the 7MM (2019–2032)

Table 11: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the US (2019–2032)

Table 12: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the US (2019–2032)

Table 13: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the US (2019–2032)

Table 14: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United States (2019–2032)

Table 15: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU-5 (2019–2032)

Table 16: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU-5 (2019–2032)

Table 17: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Germany (2019–2032)

Table 18: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in France (2019–2032)

Table 19: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Italy (2019–2032)

Table 20: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Spain (2019–2032)

Table 21: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United Kingdom (2019–2032)

Table 22: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Germany (2019–2032)

Table 23: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in France (2019–2032)

Table 24: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Italy (2019–2032)

Table 25: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Spain (2019–2032)

Table 26: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the UK (2019–2032)

Table 27: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU-5 (2019–2032)

Table 28: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Germany (2019–2032)

Table 29: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in France (2019–2032)

Table 30: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Italy (2019–2032)

Table 31: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Spain (2019–2032)

Table 32: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the UK (2019–2032)

Table 33: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU5 (2019–2032)

Table 34: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Table 35: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Table 36: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Table 37: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

List of Figures

Figure 1: Risk factors associated with IPF

Figure 2: Signs and Symptoms of IPF

Figure 3: A schematic representing the current model for the pathogenesis of IPF

Figure 4: Stages of the pathogenesis of IPF

Figure 5: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).

Figure 6: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the 7MM (2019–2032)

Figure 7: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the US (2019–2032)

Figure 8: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the US (2019–2032)

Figure 9: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the US (2019–2032)

Figure 10: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United States (2019–2032)

Figure 11: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU-5 (2019–2032)

Figure 12: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU-5 (2019–2032)

Figure 13: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Germany (2019–2032)

Figure 14: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in France (2019–2032)

Figure 15: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Italy (2019–2032)

Figure 16: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Spain (2019–2032)

Figure 17: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the United Kingdom (2019–2032)

Figure 18: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Germany (2019–2032)

Figure 19: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in France (2019–2032)

Figure 20: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Italy (2019–2032)

Figure 21: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Spain (2019–2032)

Figure 22: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the UK (2019–2032)

Figure 23: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU-5 (2019–2032)

Figure 24: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Germany (2019–2032)

Figure 25: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in France (2019–2032)

Figure 26: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Italy (2019–2032)

Figure 27: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Spain (2019–2032)

Figure 28: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the UK (2019–2032)

Figure 29: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in the EU5 (2019–2032)

Figure 30: Total Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Figure 31: Gender-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Figure 32: Age-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Figure 33: Severity-specific Diagnosed Prevalent Cases of Idiopathic Pulmonary Fibrosis in Japan (2019–2032)

Figure 34: Patient Journey

Forward to Friend

Need A Quote